Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data?
Teva Pharmaceutical Industries (NYSE:TEVA) is back on investors’ radar after its U.S. affiliate presented new Phase 3 SOLARIS data on investigational olanzapine LAI TEV-749 for adults with schizophrenia.
TEVA’s share price has climbed 18.79% year to date, and the latest 30-day share price return of 5.43% suggests momentum is still building around Teva Pharmaceutical Industries as investors weigh the SOLARIS data alongside a 95.05% 1-year total shareholder return and very strong 3 and 5-year total shareholder returns.
Scan beyond Teva Pharmaceutical Industries and see how other healthcare-focused companies with robust finances are setting up their next move with our list of solid balance sheet and fundamentals (23 results)
Bulls see Teva Pharmaceutical Industries as a discounted way into higher margin branded CNS treatments, while bears point to execution and pipeline risk. Which side does the current valuation lean toward as TEVA trades below implied value and analyst targets?
Most Popular Narrative: 7% Undervalued
The most followed valuation view pegs Teva Pharmaceutical Industries at a fair value of $42, compared with the last close at $39.01, which frames the current price as a modest discount rather than a deep bargain or an obvious premium.
The focus on immune mediated and fibrotic diseases with duvakitug and anti IL 15, including additional indications such as hidradenitis suppurativa, fibrostenotic Crohn’s disease, vitiligo and potentially celiac disease, targets therapy areas where current treatment options leave measurable unmet need. Management links this to a combined peak sales potential above US$10b and an expected lift in both revenue mix and net margins.
See why 2 investors see Teva Pharmaceutical Industries as 7% undervalued.
Result: Fair Value of $42 (UNDERVALUED)
Still, the Teva Pharmaceutical Industries story could shift quickly if the pipeline stumbles on approvals or if biosimilar contributions fall short of management ambitions.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Next Steps
Mixed signals around Teva Pharmaceutical Industries only matter if you turn them into your own judgment. Move quickly, test the assumptions, and weigh the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
Do not stop with Teva Pharmaceutical Industries when there are focused stock lists built to surface fresh ideas that match different risk and return preferences.
- Target resilience by scanning companies with stronger finances and cleaner balance sheets through the list of solid balance sheet and fundamentals (23 results).
- Hunt for potential value by reviewing the 30 high quality undervalued stocks that could suit investors who care about price relative to fundamentals.
- Find income-focused ideas by using the 7 dividend fortresses and see which high-yielding businesses fit your portfolio goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com